NAVCO PHARMACEUTICALS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.11 CAD | +10.00% |
|
+175.00% | +340.00% |
Valuation
| Fiscal Period: September | 2023 |
|---|---|
| Capitalization 1 | 1.211 |
| Enterprise Value (EV) 1 | 1.58 |
| P/E ratio | -0.42 x |
| Yield | - |
| Capitalization / Revenue | - |
| EV / Revenue | - |
| EV / EBITDA | -1.12 x |
| EV / FCF | -1,599,675 x |
| FCF Yield | -0% |
| Price to Book | 13.8 x |
| Nbr of stocks (in thousands) | 40,350 |
| Reference price 2 | 0.0300 |
| Announcement Date | 1/29/24 |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: September | 2021 | 2022 | 2023 |
|---|---|---|---|
| Net sales 1 | 0.0155 | 0.0587 | - |
| EBITDA 1 | -0.4949 | -0.4206 | -1.411 |
| EBIT 1 | -0.5138 | -0.4502 | -1.441 |
| Operating Margin | -3,309.64% | -766.48% | - |
| Earnings before Tax (EBT) 1 | -0.5263 | -0.4651 | -2.147 |
| Net income 1 | -0.5263 | -0.4651 | -2.147 |
| Net margin | -3,389.75% | -791.92% | - |
| EPS 2 | -0.0363 | -0.0321 | -0.0711 |
| Free Cash Flow | - | -0.1475 | -0.9879 |
| FCF margin | - | -251.16% | - |
| FCF Conversion (EBITDA) | - | - | - |
| FCF Conversion (Net income) | - | - | - |
| Dividend per Share | - | - | - |
| Announcement Date | 2/6/23 | 2/6/23 | 1/29/24 |
1CAD in Million2CAD
Estimates
Balance Sheet Analysis
| Fiscal Period: September | 2021 | 2022 | 2023 |
|---|---|---|---|
| Net Debt 1 | 0.57 | 0.9 | 0.37 |
| Net Cash position 1 | - | - | - |
| Leverage (Debt/EBITDA) | -1.161 x | -2.131 x | -0.262 x |
| Free Cash Flow | - | -0.15 | -0.99 |
| ROE (net income / shareholders' equity) | - | 83.7% | 613% |
| ROA (Net income/ Total Assets) | - | -83.3% | -143% |
| Assets 1 | - | 0.5587 | 1.498 |
| Book Value Per Share 2 | -0.0200 | -0.0500 | 0 |
| Cash Flow per Share 2 | 0 | 0 | 0.0100 |
| Capex 1 | 0.07 | - | - |
| Capex / Sales | 474.27% | - | - |
| Announcement Date | 2/6/23 | 2/6/23 | 1/29/24 |
1CAD in Million2CAD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +340.00% | 4.61M | |
| +12.36% | 389B | |
| +15.19% | 138B | |
| +16.01% | 75.87B | |
| -6.28% | 66.57B | |
| -15.06% | 44.54B | |
| -10.64% | 36.84B | |
| +7.37% | 35.23B | |
| +11.24% | 18.53B | |
| +19.21% | 16.08B |
- Stock Market
- Equities
- NAV Stock
- Financials NAVCO Pharmaceuticals Inc.
